08048035968
Respiratory NEOSURF 5ml Injection trusted to Canada - Toronto | Phoenix Exim | Global Exporter

1. General Information

NEOSURF is a bovine lipid extract pulmonary surfactant supplied as a sterile suspension in a 5 mL single-use vial. It is specifically formulated for intratracheal administration in newborns requiring surfactant replacement therapy. The product contains approximately 27 mg phospholipid/mL.

It is a prescription/hospital-use medicine and should be administered only by appropriately trained neonatal or medical professionals.

2. Product Information

  • Brand: NEOSURF
  • Form: Sterile suspension
  • Pack size: 5 mL vial
  • Active component: Bovine lipid extract surfactant
  • Phospholipid concentration: 27 mg/mL
  • Source: Bovine-derived pulmonary surfactant
  • Route: Intratracheal administration
  • Manufacturer/marketer: Cipla Ltd. is identified as the manufacturer/marketer in Indian product information.
  • Storage: Refrigerated storage is generally required; product information indicates storage around 2–8°C. Do not freeze.

3. Uses of NEOSURF

NEOSURF is used as surfactant replacement therapy in premature newborns with Neonatal Respiratory Distress Syndrome (NRDS). Premature infants may have insufficient natural pulmonary surfactant, making it difficult for the lungs' air sacs to remain open.

By replacing deficient surfactant, NEOSURF helps restore pulmonary surfactant activity and improve lung function.

4. Benefits of NEOSURF

Potential clinical benefits include:

  • Helps replace deficient pulmonary surfactant.
  • Reduces surface tension within the alveoli.
  • Helps prevent alveolar collapse during expiration.
  • Improves lung compliance.
  • Supports better gaseous exchange.
  • Can help improve respiratory function in premature infants with NRDS.
  • May reduce the respiratory support requirements when used appropriately as part of neonatal intensive care.

5. Side Effects

Because NEOSURF is administered directly into the airway, some reactions can occur during or shortly after administration. These may include:

  • Temporary changes in oxygen saturation
  • Changes in heart rate
  • Changes in blood pressure
  • Airway obstruction or difficulty with ventilation
  • Oxygenation changes
  • Rarely, complications related to airway administration

The infant should be continuously monitored by qualified healthcare professionals during surfactant administration.

6. Common/Important Administration-Related Effects

Possible effects associated with surfactant administration include:

  • Bradycardia or other temporary heart-rate changes
  • Oxygen desaturation
  • Changes in blood oxygen levels
  • Transient airway blockage
  • Reflux of surfactant into the endotracheal tube
  • Need for temporary adjustment of ventilator settings

These reactions require immediate clinical assessment and appropriate neonatal respiratory support.

7. How to Use NEOSURF

NEOSURF must not be self-administered. It is intended for intratracheal instillation after an endotracheal airway has been established and must be given by trained healthcare professionals.

The product information gives a recommended dose of 5 mL/kg, equivalent to 135 mg phospholipid/kg at 27 mg/mL. Additional doses may be considered by the treating neonatal team according to the infant's clinical response and the approved product information.

The vial is single-use. It should be brought to approximately room temperature and gently mixed according to the manufacturer's instructions before administration. It should not be injected intravenously or administered by another route.

8. How NEOSURF Works

Premature infants can have inadequate amounts of natural pulmonary surfactant. Without enough surfactant, surface tension inside the alveoli increases, making the air sacs more likely to collapse and impairing gas exchange.

NEOSURF supplies exogenous bovine surfactant containing phospholipids and surfactant-associated proteins SP-B and SP-C. These components help restore surfactant activity, reduce alveolar surface tension, improve lung compliance, and support more effective gaseous exchange.

9. Safety Advice

  • Use only under specialist medical supervision.
  • Administration should be performed by trained neonatal/critical-care professionals.
  • It is intended for intratracheal use only.
  • Do not administer intravenously.
  • Monitor oxygen saturation, heart rate, blood pressure and ventilation during administration.
  • Keep refrigerated according to the approved product labeling.
  • Do not freeze.
  • Do not use a vial if its appearance is abnormal or the suspension does not disperse appropriately after preparation.
  • Vials are intended for single use.
  • Tell the medical team about any relevant clinical conditions or complications affecting the newborn.
  • Follow the locally approved prescribing information because dosing and administration protocols may differ by country.

10. FAQs

Q1. What is NEOSURF 5 mL Injection used for?
NEOSURF is a pulmonary surfactant used in premature newborns with Neonatal Respiratory Distress Syndrome to replace deficient natural lung surfactant.

Q2. What is the composition of NEOSURF?
It contains bovine lipid extract surfactant with a phospholipid concentration of 27 mg/mL and surfactant-associated proteins including SP-B and SP-C.

Q3. How is NEOSURF administered?
It is administered by intratracheal instillation through an established endotracheal airway by trained medical professionals.

Q4. Can NEOSURF be given at home?
No. It is a hospital-based neonatal medicine requiring specialized airway and respiratory monitoring.

Q5. Can NEOSURF be given intravenously?
No. The product is specifically intended for intratracheal administration.

Q6. Does NEOSURF require refrigeration?
Yes. Product information indicates refrigerated storage, generally around 2–8°C, and it should not be frozen.

Q7. Is NEOSURF suitable for adults?
NEOSURF is primarily used as neonatal pulmonary surfactant therapy, particularly in premature infants with respiratory distress syndrome. Its use should follow the approved indication and specialist medical advice.

Q8. Is NEOSURF a steroid or antibiotic?
No. NEOSURF is a pulmonary surfactant, not a steroid or antibiotic.

11. Substitutes / Alternative Surfactants

There is no simple one-to-one substitute that should be selected without considering the newborn's clinical condition, gestational age, local protocols and product availability.

Other pulmonary surfactant preparations used in neonatal care include:

  • Poractant alfa (Curosurf) – porcine-derived surfactant
  • Beractant (Survanta) – bovine-derived surfactant
  • Calfactant (Infasurf) – bovine-derived surfactant

These products have different compositions, concentrations, dosing schedules and clinical evidence, so the treating neonatologist should determine the appropriate product.

12. SEO Keywords

  • NEOSURF 5 mL Injection exporter from India
  • NEOSURF 5 mL Injection supplier India
  • NEOSURF pulmonary surfactant exporter
  • NEOSURF bovine lipid extract surfactant
  • NEOSURF 27 mg/mL injection
  • NEOSURF neonatal respiratory distress syndrome medicine
  • NEOSURF surfactant injection supplier
  • NEOSURF injection pharmaceutical exporter Nagpur
  • NEOSURF 5 mL vial exporter India
  • NEOSURF injection supplier from Nagpur India
  • Bovine pulmonary surfactant exporter India
  • Neonatal surfactant medicine exporter India
  • Respiratory distress syndrome medicine supplier India
  • NEOSURF injection wholesale supplier
  • NEOSURF pharmaceutical export supplier
  • NEOSURF injection for premature infants
  • NEOSURF neonatal ICU medicine supplier
  • NEOSURF surfactant suspension exporter
  • Genuine NEOSURF injection supplier India
  • NEOSURF 5 mL pharmaceutical supplier
  • NEOSURF exporter to USA
  • NEOSURF exporter to UK
  • NEOSURF exporter to Australia
  • NEOSURF exporter to Singapore
  • NEOSURF exporter to Canada
  • NEOSURF exporter to South Korea
  • NEOSURF exporter to UAE
Aug 21st, 2026 3:11 PM

Keywords